tradingkey.logo

Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thrombocythemia

ReutersJan 12, 2026 1:03 PM

- PharmaEssentia Corp 6446.TW:

  • PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 2B DATA FROM EXCEED-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT FOR ESSENTIAL THROMBOCYTHEMIA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI